Journal of Thoracic Oncology:
FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies
Benveniste, Marcelo F.K. MD*; Moran, Cesar A. MD‡; Mawlawi, Osama PhD†; Fox, Patricia S. MS§; Swisher, Stephen G. BS, MD‖; Munden, Reginald F. DMD, MBA, MD*; Marom, Edith M. MD*
*Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX; †Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX; ‡Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX; §Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX; and ‖Department of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Disclosure: Patricia S. Fox has received a Cancer Center Support Grant P30 CA016672. Osama Mawlawi consulted Siemens. Reginald F. Munden gave expert testimony for the Federal District Attorney Office, Florida. Stephen G. Swisher serves on the Magrit Advisory Board. The other authors declare no conflict of interest. FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies.
Address for correspondence: Edith M. Marom, Department of Diagnostic Radiology, Unit 1478, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030. E-mail: email@example.com
Introduction: Advanced thymoma (stage III and IV) is difficult to detect by computed tomography (CT), yet it is important to distinguish between early (stage I and II) and advanced disease before surgery, as patients with locally advanced tumors require neoadjuvant chemotherapy to enable effective resection. This study assessed whether the amount of fluorodeoxyglucose (FDG) uptake can predict advanced thymoma and whether it can separate thymoma from thymic cancer.
Methods: We retrospectively reviewed FDG positron emission tomography (PET)-CT scans of 51 consecutive newly diagnosed patients with thymic epithelial malignancy. PET-CT findings documented focal FDG activity: SUVmax, SUVmean, SUVpeak, and total body volumetric standardized uptake value (SUV) measurements. These were correlated with Masaoka–Koga staging and World Health Organization classification. Wilcoxon ranked sum tests were used to assess association between SUV and pathological stage, cancer type, and classification.
Results: Among the study patients, 37 had thymoma, 12 thymic carcinoma, and 2 thymic carcinoid. Higher focal FDG uptake was seen in patients with type B3 thymoma than in those with type A, AB, B1, or B2 thymoma (p < 0.006). FDG uptake was higher in patients with thymic carcinoma or carcinoid than in patients with thymoma (p < 0.0003), with more variable associations with volumetric SUV measurements. There was no significant association observed between higher focal FDG uptake and advanced-stage disease in thymoma patients (p > 0.09), although greater FDG-avid tumor volume was significantly associated with advanced disease (p < 0.03).
Conclusions: Focal FDG uptake cannot predict advanced thymoma but is helpful in distinguishing thymoma from thymic carcinoma, or the more aggressive thymoma, type B3.
Thymic epithelial neoplasms include thymoma, thymic carcinoma, and carcinoid. Of these, thymoma is the most common and accounts for approximately 20% of adult anterior mediastinal neoplasms.1 Computed tomography (CT) is the most common imaging modality currently used for evaluation of the anterior mediastinal mass. However, often, it cannot differentiate early (stage I and II) from advanced (stage III and IV) disease, as local invasion into the pericardium and vessels is more difficult to appreciate than simple abutment, and fine pleural metastatic spread may be below the resolution of CT. It is important to distinguish between early and advanced disease before surgery, as patients with locally advanced tumors receive neoadjuvant chemotherapy to enable effective resection.2 Complete resection, even of advanced disease, improves survival.3
Some surgeons advocate thymectomy without biopsy for small anterior mediastinal masses suggestive of thymoma. However, early-stage thymoma, thymic cancer, and carcinoid may look identical on CT. As thymic cancer and thymic carcinoid are much more aggressive than thymoma, with a tendency for early metastatic spread, patients with these tumors usually receive neoadjuvant chemotherapy, even with clinical early disease. Therefore, identifying the specific disease before thymectomy is desirable for the betterment of therapy.
Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT has emerged as a strong diagnostic tool for the diagnosis, clinical staging, and outcome of intrathoracic malignancies, especially in patients with non–small-cell lung cancer,4,5 but the precise role of FDG PET-CT in the management of thymic epithelial malignancies, especially thymoma, is unclear. There is controversy about FDG PET-CT’s ability to differentiate between invasive and noninvasive thymomas, and only a few small studies have assessed FDG-PET imaging of thymoma, the majority of which also combined thymic cancers in their evaluation.6,7
The goal of our study was to assess whether FDG PET-CT can distinguish thymoma from thymic carcinoma and carcinoid and whether it can distinguish early from advanced thymoma, for which preoperative chemotherapy is needed.
PATIENTS AND METHODS
A retrospective search of a PET-CT database from The University of Texas MD Anderson Cancer Center revealed 140 patients who were referred for FDG PET-CT scanning for the evaluation of thymic epithelial neoplasms between October 2003 and November 2011. Of the 140 patients referred for thymic epithelial neoplasm evaluation based on their PET-CT scans, 89 patients were excluded because no pretreatment PET-CT was available for review. Therefore, the final study group comprised 51 patients for whom a pretreatment PET-CT for evaluation of a thymic epithelial malignancy was available for review. We reviewed these patients’ computerized medical records to extract demographic data, their operative, pathology, treatment reports, and their imaging studies. This study was approved by our institutional review board and we obtained a waiver of the requirement for informed consent. In addition, our study was in compliance with Health Insurance Portability and Accountability Act regulations.
We applied the Masaoka–Koga staging system8 to each case by reviewing the operative and pathology reports in consultation with an experienced pathologist specializing in thymoma (C.A.M.). This staging system is based on gross and microscopic properties of the tumor, where stage I was assigned when the tumor was completely encapsulated; stage II was assigned when there was either microscopic invasion into the capsule (IIa) or invasion into surrounding fat (IIb); stage III was assigned when there was invasion into a neighboring organ such as the pericardium, great vessels, or lung; and stage IV was assigned when there was pleural or pericardial dissemination (IVa) or lymphatic/hematogenous metastasis (IVb). The WHO classification9 for each tumor was determined (by CAM) from the operative specimen and was dichotomized into atypical thymoma (WHO type B3) and typical thymoma (WHO type A, AB, B1, and B2) for statistical purposes. Similarly, for statistical purposes, carcinoid was included with thymic carcinoma.
Integrated PET-CT systems were used to acquire imaging data (Discovery ST, STe, or RX; General Electric Healthcare, Waukesha, WI). Whole-body examinations were performed from the level of the vertex of the skull or orbits through the upper thighs. PET-CT was performed in accordance with guidelines published by the National Cancer Institute.10 All patients fasted for a minimum of 6 hours before the intravenous injection of FDG. A normal fasting blood glucose level of 80–120 mg/dl (4.4–6.6 mmol/l) was a standard requirement for imaging in all patients. PET data acquisition was performed in 2D mode before January 2008 and was changed to 3D mode after that date. For 2D imaging, an intravenous injection of 555 to 629 MBq (15–17 mCi) of FDG was administered in the arm or central venous catheter on the side opposite the cancer, and emission scans were acquired at 3 minutes per field of view 60–90 minutes after the FDG injection. The same procedure was used for 3D imaging except for using an injected dose of 333 to 407 MBq (9–11 mCi) of FDG. PET images were reconstructed using standard vendor-provided reconstruction algorithms. Noncontrast-enhanced CT images were acquired in helical mode (speed, 13.5 mm/rotation) from the base of the skull to the midthigh during suspended midexpiration at a 3.75-mm slice thickness, a tube voltage of 120 kVp, a tube current–time product of 150 mAs, and a 0.5-second rotation. Attenuation-corrected and nonattenuation-corrected datasets were reconstructed.
The PET-CT scans were reviewed by two experienced chest radiologists (M.F.K.B. and E.M.M.) who were blinded to clinical information. Differences in their findings were resolved by consensus. Imaging findings were recorded for each patient. A clinical CT stage was assigned and FDG uptake was recorded in terms of standardized uptake value body weight (SUV) as SUVmax, SUVmean, or SUVpeak. Total body volumetric SUV was calculated as the volume of tumor (in cm3) within 45% of SUVmax, and the volume of tumor (in cm3) with SUVmax above a threshold of 3.5. For these measurements SUVmean and SUVpeak were determined from the volume of interest defined by the 45% of the SUVmax.
We used Wilcoxon ranked sum tests to assess associations between SUV and pathological stage, cancer type, and WHO classification, with p values computed using the normal approximation. We used Fisher’s exact test to assess association between cancer type and pathological stage. We calculated overall survival (OS) from the date of the initial pathology diagnosis todate of death or last follow-up. We calculated progression-free survival from the date of the initial pathology diagnosis to first progression, death, or last clinical evaluation for progression. We used univariate Cox regression models to predict OS and progression-free survival time from SUV measurements. All statistical analyses were performed using SAS 9.2 for Windows (SAS Institute Inc., Cary, NC).
Patient and Disease Characteristics
Among the 51 study patients, 37 patients had a pathology diagnosis of thymoma, 12 patients had thymic carcinoma, and two patients had thymic carcinoid. Thirty patients (59%) were men and 21 patients (41%) were women. Their ages ranged from 21 to 84 years (mean: 59.4 years). Using the Masaoka–Koga pathological staging for the thymoma patients, 1 patient (3%) had stage I disease, 14 patients (37%) had stage IIa disease, five patients (13%) had stage IIb disease, eight patients (22%) had stage III disease, seven patients (19%) had stage IVa disease, and two patients (6%) had stage IVb disease. Among the 14 patients with thymic carcinoma or thymic carcinoid, one patient (7%) had stage I disease, six patients (43%) had stage III disease, three patients (21%) had stage IVa disease, and four patients (29%) had stage IVb disease. Patients with thymoma were more likely to present with early-stage disease (n = 20; 54%) than were patients with thymic carcinoma and carcinoid (n = 1; 7%) (p = 0.003) (Table 1). Of the 37 thymoma patients, surgical specimens for 36 were available for histological classification review. Most were confirmed to have typical thymoma: WHO classification type A in eight patients (22%), type AB in three patients (8%), type B1 in 10 patients (27%), and type B2 in nine patients (24%); only seven patients (19%) presented with atypical thymoma (type B3) (Table 2).
PET-CT and Tumor Classification
The FDG uptake of thymic carcinoma and thymic carcinoid was significantly higher than that of thymoma, as measured by SUVmax (p = 0.0001), SUVpeak (0.0003), SUVmean (0.0001), and total tumor volume above SUVmax 3.5 (p = 0.02), but not by volumetric measurement calculated as total tumor volume, within 45% of SUVmax (p = 0.74) (Table 3) (Figs. 1–3). Using an SUVmax value of 6 or more to classify everything above this as thymic cancer/carcinoid, 100% of thymic cancer/arcinoid tumors were correctly identified but 38% of thymoma patients were classified as thymic cancer. A value of 7 or more misclaffied thymic cancer as thymoma, whereas a value of five resulted in 59% of thymomas misclassified as thymic cancer. When assessing whether FDG uptake differentiated between the different thymoma WHO classification types, we found that higher FDG uptake did distinguish B3 thymoma from the other types combined when FDG uptake was measured in terms of SUVmax (p = 0.006), SUVpeak (p = 0.004), and SUVmean (p = 0.005), and total tumor volume above SUVmax 3.5(p = 0.04) (Figs. 4 and 5), but not when it was recorded as the volumetric measurement calculated as total tumor volume within 45% of SUVmax (p = 0.78) (Table 4). When trying to differentiate thymoma WHO types B2 and B3 from types A, AB, and B1, we found a weak association only for total tumor volume measurement above SUVmax 3.5 (p = 0.05), not for the other SUV measurements (p > 0.08) (Table 5).
PET-CT and Tumor Staging
FDG uptake was higher for patients with epithelial thymic malignancies presenting with advanced disease (Table 6) (p < 0.01) than for patients with early-stage disease. However, when excluding thymic carcinoma and thymic carcinoid and assessing the association of FDG uptake with the Masaoka–Koga stage for thymomas only, there was no association between higher FDG activity and advanced disease measured by SUVmax (p = 0.135), SUVpeak (p = 0.097), and SUVmean (p = 0.206) (Figs. 2 and 6). Greater volumes of FDG-avid tumor did correlate with advanced stage, as measured by tumor volume above 45% of SUVmax (p = 0.002), and tumor volume above SUVmax 3.5 (p = 0.029) (Table 7).
Because of the clinical need to distinguish patients who have clinical Masaoka–Koga stage early disease from those who have locally advanced disease (stage III) at the time of initial staging CT, we also assessed whether the FDG uptake could differentiate early from advanced disease in our patient group. In this group of patients with clinical stage I–III epithelial thymic malignancies, the amount of FDG uptake, whether measured as SUVmax, SUVmean, or SUVpeak or whether measured volumetrically, could not stratify patients into the groups defined by disease stage (p = 0.078–0.183). Similar results were seen when evaluating only the patients with clinical stage I–III thymoma: the amount of FDG uptake, whether measured as SUVmax, SUVmean, or SUVpeak or measured volumetrically, could not stratify patients into early and advanced disease groups (p = 0.21–0.93) (Table 8).
PET-CT and Outcome
Follow-up medical information was available for 50 of the 51 patients who presented with a thymic epithelial malignancy. Patients were followed for a median of 942 days (ranges,139–3801 days). Fourteen patients had progression of disease and seven patients died. FDG uptake was not a predictor of progression-free survival time (p > 0.12) nor of OS (p > 0.06).
Follow-up medical information was available for all 37 patients who presented with thymoma. They were followed-up for a median of 1049 days (ranges, 139–3801 days). Six patients had progression of disease and two patients died. FDG uptake could neither be used as a valid predictor of progression-free survival (p > 0.11) nor of OS (p > 0.10).
Our study has shown that higher FDG uptake is associated with the more aggressive forms of thymic epithelial malignancies, thymic carcinoma, and thymic carcinoid, but it has also shown that focal FDG uptake cannot distinguish early from advanced disease in patients presenting with thymoma.
Thymoma is more common but carries a better prognosis than thymic carcinoma.11 Studies assessing the use of FDG PET in thymic epithelial malignancies have been small, reviewing from 10 to 49 patients only.12 Early results consistently showed that FDG uptake as measured by SUVmax was much higher in thymic carcinoma than in thymoma, a finding supported by our study as well,7,13–18 and correlates with the more aggressive nature of thymic carcinoma.
Our study has also shown that the user-friendly point of maximal FDG uptake, SUVmax, available on any workstation, or the SUVpeak found on some workstations, correlated better with histology than the more cumbersome volumetric measurements. This finding is useful for treatment planning for patients presenting with smaller masses suggestive of thymic epithelial malignancy because there are surgeons who advocate resection of such masses without preoperative biopsy confirmation. This could be problematic in cases of thymic cancer, for which neoadjuvant chemotherapy is commonly used because of the cancer’s aggressiveness and in cases of nonsurgical/hematological malignancies such as lymphoma. Knowing the FDG uptake can help navigate patients to the correct treatment plan. Patients with lower FDG uptake would be presumed to have thymoma and would require surgery, whereas those with higher FDG uptake would have a biopsy performed to test for either thymic cancer or lymphoma.18,19 Although we found the best value for this approach to be SUVmax value of 6 or more, this should be interpreted with caution, as a similar study found the best value to be SUVmax value of 5 or more.19 FDG uptake quantification is affected by many technical factors which vary from one institution to the other and is affected by physiologic factors which can alter the SUV by more than 50%.20
Imaging studies so far have used a simplified system of low-risk (type A, AB, and B1) thymoma and compared them to high-risk (type B2 and B3) thymomas, but this has produced variable results. Two studies showed that FDG PET helped differentiate low-risk from high-risk thymoma (type B2 and B3),14,18 whereas two other studies showed that it did not.7,15 Because of these variable results, we sought to determine whether a different simplification of the WHO system, separating type B3 from the more indolent forms of thymoma, would better correlate with FDG uptake.21 We chose this form of classification in view of a recent study that assessed 250 thymoma patients and showed that type B3 thymoma has a significantly worse prognosis than the other types.22,23 Indeed, in our study, FDG uptake was much higher when type B3 was separated from types A through B2. This is of clinical importance, not only for those patients who do not routinely undergo a biopsy procedure before surgery but also for those who do, as thymoma is a heterogeneous tumor and a biopsy does not always sample the most aggressive part of it. Therefore, the FDG uptake could be used to direct those patients with a worse prognosis towards neoadjuvant therapy, whether they are part of the high-risk thymoma group (type B3) or the thymic carcinoma group.24–26 This is also useful as type B3 thymoma and thymic carcinoma have been shown in larger studies to usually present with advanced (stage III or IV) disease.24–26
In thymoma, the separation of early disease from advanced disease, the latter of which requires neoadjuvant therapy, is the most important goal in this clinical staging. Because most stage III thymomas do not present with direct signs of invasion on morphological imaging (CT or magnetic resonance imaging), recognizing locally advanced disease is challenging and often relies on indirect signs rather than the visualization of the invasion itself.27 Having a physiological marker to help in the differentiation of advanced disease would be helpful. Unfortunately, we found that none of the volumetric FDG uptake metrics we assessed were helpful in separating early from advanced disease. We chose to assess FDG as measured by both SUVmax and SUVpeak because SUVmax is the method that is used most often for evaluating FDG uptake and is currently available on all commercially available PET-CT workstations. Because SUVmax is based on a single voxel value, its reproducibility is not as good as that of SUVpeak, which assesses a volume of approximately 1 cm3 around the area of maximal FDG uptake.28 Our study is in agreement with another investigation17 that confirmed the inability of FDG SUVmax to predict thymoma invasiveness. For many cancers, there is an ongoing fundamental debate about whether tumor prognosis and response to therapy are best evaluated by measuring tumor volume or by quantifying the most metabolically active portion of the tumor.29–34 It is for this reason that we chose to measure FDG’s highest focal activity and its total metabolic volume. Of note, higher volumes of metabolic tumor did correlate with advanced disease. This, however, may have been because of the tumor size itself rather than its metabolic activity, as larger tumors are known to be associated with higher stages of disease.27 When patients with obvious clinical stage IV disease were excluded from this analysis, however, the association between total metabolic volume and advanced disease was no longer preserved, showing that, for thymic epithelial tumors, cumbersome volumetric measurements are probably not worthwhile.
The presence of higher FDG uptake in many tumors has been shown to be associated with a worse outcome, regardless of stage.35–39 We could not find such an association for thymic epithelial malignancies in our study. It remains to be seen if FDG uptake will prove useful for monitoring the response of nonresectable thymic epithelial malignancies. A preliminary study of a subgroup of patients with nonresectable thymic epithelial malignancies has shown that OS was longer for those patients who had partial metabolic responses to treatment than for those who did not.40
Our study’s main limitations relate to its retrospective nature and the small number of patients evaluated. However, it represents the largest series published so far of patients with this studied rare disease.12 In addition, many prior studies have analyzed mixed populations of patients with thymic carcinoma and thymoma, creating difficulties in drawing conclusions that might be implemented into daily clinical use. We thus deliberately analyzed thymoma patients separately from thymic carcinoma patients so that our findings could inform daily clinical decision making.
In conclusion, although FDG PET-CT is an excellent tool for the assessment of the patient presenting with an anterior mediastinal mass and can be used to differentiate thymic carcinoma from thymoma, FDG uptake is not helpful in determining the disease stage. Thus for the time being, this imaging modality is reserved for detecting those patients more likely to require preoperative chemotherapy, such as patients with thymic carcinoma or the more aggressive type of thymoma, type B3.
1. Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest. 2005;128:2893–2909
2. Casey EM, Kiel PJ, Loehrer PJ Sr. Clinical management of thymoma patients. Hematol Oncol Clin North Am. 2008;22:457–473
3. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg. 1995;60:908–913; discussion 914
4. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;229:526–533
5. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011–1019
6. Endo M, Nakagawa K, Ohde Y, et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer. 2008;61:350–355
7. Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med. 2006;47:1628–1634
8. Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44:359–367
9. Travis WD, Brambilla E, Muller-Hermelik HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. 2004 Lyon IARC Press
10. Shankar LK, Hoffman JM, Bacharach S, et al.National Cancer Institute. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059–1066
11. Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol. 2011;6(7 Suppl 3):S1698–S1704
12. Kaira K, Sunaga N, Ishizuka T, Shimizu K, Yamamoto N. The role of [18
F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors. Cancer Imaging. 2011;11:195–201
13. Igai H, Matsuura N, Tarumi S, et al. Usefulness of [18F]fluoro-2-deoxy-D-glucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors. Eur J Cardiothorac Surg. 2011;40:143–145
14. Kaira K, Endo M, Abe M, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 2010;28:3746–3753
15. Kumar A, Regmi SK, Dutta R, et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med. 2009;23:569–577
16. Sasaki M, Kuwabara Y, Ichiya Y, et al. Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET. J Nucl Med. 1999;40:1595–1601
17. Shibata H, Nomori H, Uno K, et al. 18F-fluorodeoxyglucose and 11C-acetate positron emission tomography are useful modalities for diagnosing the histologic type of thymoma. Cancer. 2009;115:2531–2538
18. Terzi A, Bertolaccini L, Rizzardi G, et al. Usefulness of 18-F FDG PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms. Lung Cancer. 2011;74:239–243
19. Luzzi L, Campione A, Gorla A, et al. Role of fluorine-flurodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses. Eur J Cardiothorac Surg. 2009;36:475–479
20. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S–20S
21. Suster S, Moran CA. Histologic classification of thymoma: the World Health Organization and beyond. Hematol Oncol Clin North Am. 2008;22:381–392
22. Moran CA, Walsh G, Suster S, Kaiser L. Thymomas II: a clinicopathologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment. Am J Clin Pathol. 2012;137:451–461
23. Moran CA, Weissferdt A, Kalhor N, et al. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol. 2012;137:444–450
24. Chen G, Marx A, Chen WH, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer. 2002;95:420–429
25. Fang W, Chen W, Chen G, Jiang Y. Surgical management of thymic epithelial tumors: a retrospective review of 204 cases. Ann Thorac Surg. 2005;80:2002–2007
26. Lee HS, Kim ST, Lee J, et al. A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management. Br J Cancer. 2007;97:22–28
27. Marom EM, Milito MA, Moran CA, et al. Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol. 2011;6:1274–1281
28. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–150S
29. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004;14:43–47
30. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006;107:431–434
31. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–1037
32. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68:190–197
33. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264:559–566
34. Liu F, Zhao B, Krug LM, et al. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans. J Thorac Oncol. 2010;5:879–884
35. Al-Sarraf N, Gately K, Lucey J, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg. 2008;34:892–897
36. Berghmans T, Dusart M, Paesmans M, et al.European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3:6–12
37. Sharif S, Zahid I, Routledge T, Scarci M. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg. 2011;12:806–811
38. Zhang B, Li X, Lu X. Standardized uptake value is of prognostic value for outcome in head and neck squamous cell carcinoma. Acta Otolaryngol. 2010;130:756–762
39. Costelloe CM, Macapinlac HA, Madewell JE, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009;50:340–347
40. Kaira K, Murakami H, Miura S, et al. 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med. 2011;25:247–253
Thymoma; PET-CT; Masaoka–Koga
© 2013International Association for the Study of Lung Cancer
Highlight selected keywords in the article text.